Anti-tumor activity in preclinical models utilizing a conditional bispecific redirected activation molecule (COBRA) targeting Her2

被引：1
|
作者：
Stringer, Bradley
Chouitar, Johara
Cerbone, Jacqualine
Fortin, Sarah
Ainbinder, Alina
Kysilovsky, Cassie
Scott, Brittany
Banerjee, Antara
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB063
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Anti-tumor effect of Dasatinib in HER2 positive breast cancer with Trastuzumab resistance
    Takeda, Tatsuaki
    Kanzaki, Hirotaka
    Toyooka, Shinichi
    Watanabe, Mototsugu
    Ohtsuka, Tomoaki
    Suzawa, Ken
    Hashida, Shinsuke
    Maki, Yuho
    Yamamoto, Hiromasa
    Soh, Junichi
    Asano, Hiroaki
    Tsukuda, Kazunori
    Miyoshi, Shinichiro
    Kitamura, Yoshihisa
    Sendo, Toshiaki
    CANCER RESEARCH, 2015, 75
  • [22] Novel Targeting Of Phospho-Marcks Overcomes Drug Resistance and Induces Anti-Tumor Activity In Preclinical Models Of Multiple Myeloma
    Yang, Yijun
    Saha, Manujendra N.
    Chen, Yan
    Qiu, Lugui
    Reece, Donna E.
    Chang, Hong
    BLOOD, 2013, 122 (21)
  • [23] Preclinical evaluation of eFT226, a potent and selective eIF4A inhibitor with anti-tumor activity in FGFR1,2 and HER2 driven cancers
    Thompson, Peggy A.
    Young, Nathan P.
    Gerson-Gurwitz, Adina
    Eam, Boreth
    Goel, Vikas
    Stumpf, Craig R.
    Chen, Joan
    Parker, Gregory S.
    Fish, Sarah
    Barrera, Maria
    Sung, Eric
    Staunton, Jocelyn
    Chiang, Gary G.
    Webster, Kevin R.
    CANCER RESEARCH, 2020, 80 (16)
  • [24] A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy
    Chen, Yi-Li
    Cui, Yue
    Liu, Xinyuan
    Liu, Guojian
    Dong, Xingchen
    Tang, Lei
    Hung, Yifeng
    Wang, Chunhe
    Feng, Mei-Qing
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2021, 297 (06)
  • [25] A bispecific HER2/CD3 targeting FynomAb with excellent tumor killing and favorable pharmacokinetic properties
    Wuellner, Ulrich
    Buller, Fabian
    Klupsch, Kristina
    Brack, Simon
    Zbinden, Irene
    Santimaria, Roger
    Attinger-Toller, Isabella
    Koenig-Friedrich, Susann
    Bertschinger, Julian
    Grabulovski, Dragan
    CANCER RESEARCH, 2014, 74 (19)
  • [26] Emerging Challenges of Preclinical Models of Anti-tumor Immunotherapeutic Strategies Utilizing Vγ9Vδ2 T Cells
    Joalland, Noemie
    Scotet, Emmanuel
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [27] Preclinical Development of Synthetic DNA Delivery Technology for the In Vivo Launch of a Bispecific T Cell-Engager Targeting HER2
    Smith, Trevor
    Thorne, Amy
    Malo, Kirsten
    Schultheis, Katherine
    Maricic, Igor
    Guimet, Diana
    Yan, Jian
    Wong, Ashley
    Park, Daniel
    Park, Daniel
    Park, Daniel
    Gary, Ebony
    Bhojnagarwala, Pratik
    Patel, Ami
    Perales-Puchalt, Alfredo
    Muthumani, Kar
    Weiner, David
    Skolnik, Jeffrey
    Humeau, Laurent
    Broderick, Kate
    MOLECULAR THERAPY, 2020, 28 (04) : 150 - 150
  • [28] Tucatinib, a HER2-selective tyrosine kinase inhibitor, increases the anti-tumor activity of trastuzumab antibody-drug conjugates in preclinical models of HER2+breast cancer
    Kulukian, Anita
    Taylor, Janelle
    Olson, Devra
    Zaval, Margo
    Thurman, Robert
    Hengel, Shawna
    Farr, Lauren
    Lewis, Tim S.
    Peterson, Scott R.
    CANCER RESEARCH, 2020, 80 (04)
  • [29] Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
    Kawano, Satoshi
    Grassian, Alexandra R.
    Tsuda, Masumi
    Knutson, Sarah K.
    Warholic, Natalie M.
    Kuznetsov, Galina
    Xu, Shanqin
    Xiao, Yonghong
    Pollock, Roy M.
    Smith, Jesse S.
    Kuntz, Kevin K.
    Ribich, Scott
    Minoshima, Yukinori
    Matsui, Junji
    Copeland, Robert A.
    Tanaka, Shinya
    Keilhack, Heike
    PLOS ONE, 2016, 11 (07):
  • [30] Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities
    Liu, Jiayu
    Wu, Xiaoqiong
    Lin, Limin
    Pan, Haitao
    Wang, Yanlan
    Li, Yumei
    Zhao, Yining
    Wang, Zhong
    MOLECULAR THERAPY-ONCOLYTICS, 2019, 14 : 66 - 73
12345